Dyadic Announces Senior Management Changes and Other Events

Announces Senior Management Changes and Other Events

Fla - October 1, 2007 - Dyadic International, Inc. (AMEX: DIL) announced today

that on September 27, 2007, Dr. Glenn E. Nedwin resigned from all positions

Dyadic International, Inc. (the "Company"), including his positions as a member

of the Company's Board of Directors (the "Board of Directors") and Executive

Committee of the Board of Directors (the "Executive Committee"), interim

President, Chief Scientific Officer and Executive Vice President of the Company

and President of the Company's BioPharma Business. The Company has been advised

that Dr. Nedwin has accepted a position with Danisco A/S.

Company intends to commence a search to fill the position of Chief Scientific

Officer and President of the Company's BioPharma Business, although no assurance

can be given that the Company will be successful in the search, or the timing

any successful search, to replace Dr. Nedwin with a person of equal

September 29, 2007, the Executive Committee took the following personnel

business experience of Mr. Moor, Ms. De La Pointe and Mr. Bondar is summarized

on the Company's website at www.dyadic.com.

September 26, 2007, the Board of Directors expanded the membership of the

Executive Committee to include all of the directors of the Company other than

Mark Emalfarb. After the resignation of Dr. Nedwin on September 27, 2007, the

Executive Committee is comprised of Harry Rosengart, Stephen Warner, Richard

Berman and Wayne Moor. The Executive Committee, which had previously been

created by the Board of Directors on April 23, 2007, was authorized by the

of Directors to exercise all of the powers and authorities of the Board of

Directors in the management of the business and affairs of the Company to the

fullest extent permitted by applicable law and the Company's by-laws.

September 25, 2007, Mark Emalfarb submitted an arbitration demand to the

American Arbitration Association against the Company pursuant to the terms

his employment agreement dated as of April 1, 2001 as amended by the first

amendment to employment agreement dated as of March 16, 2006. The arbitration

demand contests the Company's termination for cause of Mr. Emalfarb's employment

as Chief Executive Officer and President of the Company, as described in the

Company's Current Report on Form 8-K filed with the SEC on September 24, 2007.

Company also announced today that it intends to engage an investment banker

assist it in exploring strategic alternatives for the Company in order to

maximize shareholder value. While the Company will commence exploring strategic

alternatives, no timetable has been established and no assurance can be given

to the ultimate outcome of this initiative.

International, Inc. is a biotechnology company that uses its patented and

proprietary technologies to conduct research and development activities for

discovery, development, and manufacture of products and enabling solutions

the bioenergy, industrial enzyme and pharmaceutical industries.

Statement for Forward-Looking Statements

statements contained in this press release are "forward-looking statements."

These forward-looking statements involve risks and uncertainties that could

cause our actual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by

such forward-looking statements. For a discussion of these risks and

uncertainties, please see our filings from time to time with the Securities

Exchange Commission, which are available free of charge on the SEC's web site

http://www.sec.gov, including our Annual Report on Form 10-KSB for the year

ended December 31, 2006, and our subsequent filings with the SEC. Except as

required by law, we expressly disclaim any intent or obligation to update any

forward-looking statements.

Relations, 561-743-8333

Berkman, 310-826-5051